Workflow
NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares
NAMSNewAmsterdam Pharma pany N.V.(NAMS) Newsfilter·2024-12-13 22:16

Core Viewpoint - NewAmsterdam Pharma Company N.V. has successfully closed a public offering of ordinary shares and pre-funded warrants, raising approximately 452.6milliontosupportitsdevelopmentoforal,non−statinmedicinesforcardiovasculardiseasepatients[1][2].Group1:OfferingDetails−Thepublicofferingincluded14,667,347ordinarysharespricedat452.6 million to support its development of oral, non-statin medicines for cardiovascular disease patients [1][2]. Group 1: Offering Details - The public offering included 14,667,347 ordinary shares priced at 24.50 each, with an additional 2,550,000 shares purchased through underwriters' options [1]. - Pre-funded warrants to purchase 4,882,653 ordinary shares were also offered at a price of 24.4999each,reflectingaminimalexerciseprice[1].−Thetotalnetproceedsfromtheoffering,afterdeductingunderwritingdiscountsandcommissions,amountedtoapproximately24.4999 each, reflecting a minimal exercise price [1]. - The total net proceeds from the offering, after deducting underwriting discounts and commissions, amounted to approximately 452.6 million [2]. Group 2: Company Background - NewAmsterdam Pharma is a late-stage biopharmaceutical company focused on developing therapies for patients with elevated low-density lipoprotein cholesterol (LDL-C) who are at risk of cardiovascular disease [6]. - The company is investigating obicetrapib, a once-daily CETP inhibitor, in multiple phase 3 studies as a potential LDL-C lowering therapy, either alone or in combination with ezetimibe [6].